Merck Enlicitide Lowers LDL vs Non-Statins Merck's enlicitide showed ~38% LDL reduction vs ~11% for non-statins (Mar 30, 2026 report); the oral PCSK9 candidate could broaden treatment but faces regulatory and payer hurdles.

Merck Enlicitide Lowers LDL vs Non-Statins: Merck's enlicitide showed ~38% LDL reduction vs ~11% for non-statins (Mar 30, 2026 report); the oral PCSK9 candidate could broaden treatment but faces regulatory and payer hurdles. 👈 Read full analysis #Merck #Enlicitide #LDL #PCSK9 #Cholesterol

Oral #enlicitide lowered LDL-C, #ApoB, & non-HDL-C more than oral non-statin comparators at day 56 in statin-treated adults with a history of a major #ASCVD event or at increased risk for a first event. https://bit.ly/47Ao7hw

#ACC26 #JACC #PCSK9i #CardioSky

Enlicitide substantially lowers LDL-C in people at risk for atherosclerotic CVD events The oral PCSK9 inhibitor enlicitide significantly reduces LDL-cholesterol levels in people with a history of, or risk for, atherosclerotic cardiovascular disease events.

#MedNews - The oral PCSK9 inhibitor #enlicitide significantly reduces LDL-C levels in people with a history of, or risk for, #ASCVD events.

Full story 👉 buff.ly/jS4MBME

#CardioSky

Oral PCSK9 Therapy And The Future Of Heart Disease - Dr. Christie Ballantyne MD, Baylor College of Medicine & Dr. Alexander Tal, MD join me on Progress, Potential, And Possibilities #Cardiology #Atherosclerosis #HeartDiseasePrevention #Enlicitide #PCSK9 - www.youtube.com/watch?v=ANPe...